High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation

Annals of Hematology

Volumn 84, Issue 11, 2005, Pages 748-754

  Bug, Gesine ^a   Atta, Johannes ^a   Klein, Stefan A ^a   Hertenstein, Bernd ^b   Bergmann, Lothar ^a   Boehrer, Simone ^a   Mousset, Sabine ^a   Hoelzer, Dieter ^a   Martin, Hans ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute myeloid leukaemia; Allogeneic stem cell transplantation; High dose melphalan; Refractory; Relapse

Indexed keywords

AMSACRINE; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; MELPHALAN; MITOXANTRONE; MORPHINE; THIOTEPA; TOPOTECAN; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVING DONOR; MALE; MOUTH DISEASE; MUCOSA INFLAMMATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT STUDY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; SIBLING; TREATMENT FAILURE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MELPHALAN; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 26844503712     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1075-8     Document Type: Article

References (22)

1. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502 10.1056/ NEJMoa032290
2. Bergmann L, Heil G, Denzlinger C, Raghavachar A, Duerk H, Doehner H, Einsele H, Ganser A, Hoelzer D, Hoechsmann B (2002) Triple combination of mitoxantrone, topotecan, araC (MTC) in relapsed or refractory AML. ASCO Proc 21:271a
3. Bergmann L, Heil G, Einsele H, Duerk H, Rhagavachar A, Ganser A, Hoelzer D, Hoechsmann B (2003) A multicenter study with mitoxantrone, topotecan, and cytarabine in patients with relapsed or refractory AML or in CML blast crisis - an interim analysis. Onkologie 26(Suppl):86
4. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC, Van der Lelie J, Vellenga E, Gratwohl A, Verhoef GE, Verdonck LF, Lowenberg B (2005) Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: A prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 128:59-65 10.1111/j.1365-2141.2004.05282.x
5. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, Vellenga E, De Greef GE, Jacky E, Van der Lelie J, Boogaerts MA, Lowenberg B (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969-1978 10.1200/JCO.2005.06.027
6. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 18:3918-3924 1:STN:280:DC%2BD3M%2Fnt1Gjug%3D%3D
7. de la Rubia J, Sanz GF, Martin G, Sempere A, Picon I, Carral A, Larrea L, Martinez J, Soler MA, Bonanad S, Lopez F, Jarque I, Sanz MA (1996) Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. Bone Marrow Transplant 18:1167-1173 8971390
8. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S (2004) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104:865-872 10.1182/blood-2003-11-3750
9. de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt S (2000) High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant 26:333-338 10.1038/sj.bmt.1702521
10. Ehninger G, Platzbecker U, Thiede C, Illmer T, Schuler US, Schaich M, Bornhäuser M 2004 Early allogeneic hematopoietic cell transplantation during induction chemotherapy in high-risk acute myeloid leukemia. Blood 104 abstr. 2299
11. Fung HC, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G, Sahebi F, Senitzer D, O'Donnell MR, Stein A, Snyder DS, Spielberger R, Bhatia R, Falk P, Molina A, Nademanee A, Parker P, Kogut N, Popplewell L, Vora N, Margolin K, Forman SJ (2003) Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. Biol Blood Marrow Transplant 9:649-656 10.1016/S1083-8791(03)00241-6
12. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1,065 patients entered into the United Kingdom MRC AML11 trial. Blood 98:1312-1320 10.1182/ blood.V98.5.1312
13. Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, Lubbert M, Noens L, Schlimok G, Arnold R, Kirchner H, Ganser A (2004) Risk-adapted induction and consolidation therapy in adults with de novo AML aged
14. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Togel F, Wittkowsky G, Kuse R, Zander AR (2002) Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100:755-760 10.1182/ blood-2002-01-0131
15. Leopold LH, Willemze R (2002) The treatment of acute myeloid leukemia in first relapse: A comprehensive review of the literature. Leuk Lymphoma 43:1715-1727 10.1080/1042819021000006529
16. Magagnoli M, Castagna L, Bramanti S, Balzarotti M, Santoro A (2004) Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: An effective, and well-tolerated conditioning regimen. Bone Marrow Transplant 33:1067-1068 10.1038/ sj.bmt.1704492
17. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, Francois S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL (2002) Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the IFM 9502 randomized trial. Blood 99:731-735 10.1182/blood.V99.3.731
18. Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S, Mehta J (2002) The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 100:1641-1647 10.1182/blood-2002-03-0776
19. Ringden O, Labopin M, Gorin NC, Meloni G, Blaise D, Reiffers J, Carlson K, Fouillard L, Frassoni F (2000) The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 25:1053-1058 10.1038/sj.bmt.1702409
20. Sayer HG, Kröger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K, Schwerdtfeger R, Siegert W, Runde V, Theuser C, Martin H, Schetelig J, Beelen DW, Fauser A, Kienast J, Hföfken K, Ehninger G, Bornhäuser M (2003) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31:1089-1095 10.1038/sj.bmt.1704062
21. Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Dohner K, Ganser A, Dohner H, Heil G (2004) Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German acute myeloid leukemia intergroup. J Clin Oncol 22:3741-3750 10.1200/JCO.2004.03.012
22. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254 1:CAS:528:DC%2BD3MXltlShtbw%3D